Overview

Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence

Status:
Completed

Trial end date:
2016-11-01

Target enrollment:

Participant gender:

Summary

Phase III, randomized, double-blind, double-dummy, active-controlled, parallel group multi-center trial, designed to evaluate the non-inferiority of CAM2038 compared to an existing standard of care (SL BPN/NX) in initiation and maintenance treatment with BPN.

Phase:

Phase 3

Details

Lead Sponsor:

Braeburn Pharmaceuticals

Treatments:

Buprenorphine